Search clinical trials for: Dapagliflozin 10 mg tablets

Total 2995 results

Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin (JNJ-28431754) in Healthy Indian Volunteers

Healthy

India
University of Edinburgh
AstraZeneca; NHS Lothian

Recruiting

The DAPA-MEMRI Trial (DAPA-MEMRI)

Heart Failure | Diabetic Cardiomyopathies

United Kingdom
Janssen Research & Development, LLC

Completed

An Efficacy, Safety, and Tolerability Study of Canagliflozin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Monotherapy

Diabetes Mellitus, Type 2

United States, Romania, Canada, Russian Federation, Czech Republic, Slovakia, Mexico
Janssen Research & Development, LLC

Completed

A Study to Assess the Pharmacokinetics and Pharmacodynamics of Canagliflozin in Healthy Chinese Volunteers

Healthy

China
Disphar International B.V.

Withdrawn

Bioequivalence Study of Gliclazide 120 mg Modified Release Tablets

Comparative Bioavailability

Jordan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of the Addition of Canagliflozin in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin and Sitagliptin

Diabetes Mellitus, Type 2

United States, Australia, Germany, Canada, France
Phoenicis Therapeutics

Not yet recruiting

Study of PTW-002 in Patients With Dominant or Recessive Dystrophic Epidermolysis Bullosa Due to Mutation(s) in Exon 73 of the COL7A1 Gene

Dystrophic Epidermolysis Bullosa

United States
Kanion & Huawe Medicine Co.,Ltd

Terminated

Lorcaserin and Behavioral Modification for Overweight and Obesity Management in Chinese Obese Patients

Obesity

China
Teva Pharmaceuticals USA

Completed

Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fed

Healthy

Canada
Janssen-Cilag International NV

Completed

A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42847922 in Healthy Participants

Healthy

Germany
Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Completed

KN026 in Patients With HER2 Expressing Gastric/Gastroesophageal Junction Cancer

Gastric/Gastroesophageal Junction Cancer

China
Royal Perth Hospital

Recruiting

Effects of Sodium-glucose Co-transporter-2( SGLT-2 ) Inhibition on Sympathetic Nervous System Activity in Humans (EMPA-SNS)

Obesity | Type 2 Diabetes Mellitus | Metabolic Syndrome

Australia
Yaounde Central Hospital
University of Yaounde 1

Completed

Effect of Morning Versus Evening Perindopril on Blood Pressure Control in People With Type 2 Diabetes (CHRONIC1)

Hypertension | Diabetes Mellitus, Type 2
AstraZeneca
Bristol-Myers Squibb

Completed

A Phase III Study of BMS-512148 (Dapagliflozin) in Patients With Type 2 Diabetes Who Are Not Well Controlled With Diet and Exercise

Type 2 Diabetes

United States, Canada, Mexico, Russian Federation
University of Sao Paulo General Hospital

Completed

POST-CABGDM: Empagliflozin in Perioperative CABG (POST-CABGDM)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury | Coronary Artery Bypass Surgery

Brazil
Heptares Therapeutics Limited

Completed

Comparison of Blood Levels of HTL0016878 From an Oral Capsule and an Oral Solution

Healthy Subjects

United Kingdom
MedImmune LLC

Completed

A Phase 1 Study to Evaluate the Safety of MEDI7814 in Adult Volunteers

Healthy Subjects

United States
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
Shire

Completed

Once-daily Oral Modified Release Hydrocortisone in Patients With Adrenal Insufficiency

Adrenal Insufficiency
SINA Health Education and Welfare Trust
Horizon Pharmaceutical Pvt Ltd

Completed

Evaluating the Efficacy and Safety of Empagliflozin Addition to Insulin and Oral Antidiabetic Medication (OAD) Regimen in Poorly Controlled Type 2 Diabetes and Obese Patient

Glucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Hypoglycemic Agents | Empagliflozin

Pakistan
Cantex Pharmaceuticals

Recruiting

Azeliragon and Chemoradiotherapy in Newly Diagnosed Glioblastoma

Glioblastoma

Spain
MedImmune LLC

Completed

Phase 1 Single-ascending Dose Study to Evaluate Safety and Tolerability of MEDI4920 in Healthy Adults

Healthy Volunteer

United Kingdom
AgeneBio
National Institute on Aging (NIA)

Completed

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease (HOPE4MCI)

Mild Cognitive Impairment | Prodromal Alzheimer's Disease

United States, Canada
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
Caliway Biopharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Efficacy and Safety of CBL-514 in Participants With Dercum's Disease Lipomas

Dercum's Disease

United States
Solvay Pharmaceuticals

Completed

A Controlled-Study of Fenofibrate 145 mg and Ezetimibe 10 mg in Type IIb Dyslipidemic Patients With Features of the Metabolic Syndrome

Hyperlipidemia Combined

Belgium, France, Germany
GlaxoSmithKline

Completed

First Time in Human Study Using GSK2330672

Diabetes Mellitus, Type 2

United States
Taisho Pharmaceutical Co., Ltd.

Completed

Phase III Study of TS-142 in Patients With Insomnia

Patients With Insomnia

Japan
Shaheed Zulfiqar Ali Bhutto Medical University

Completed

Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

Cytokine Release Syndrome | Covid-19 Pneumonia

Pakistan
CHC MontLégia

Active, not recruiting

Daily Monitoring of Respiratory Symptoms and Spirometry During ETI Treatment in Persons With Cystic Fibrosis.

Cystic Fibrosis

Belgium
Cycle Pharmaceuticals Ltd.
Parexel

Completed

Bioequivalence Study of Two Nitisinone Formulations Compared to Orfadin

Hereditary Tyrosinemia, Type I

South Africa
Bioprojet

Completed

Dose Range Finding Study of BF2.649 Versus Placebo to Treat Excessive Daytime Sleepiness in Parkinson's Disease Patients

Parkinson's Disease | Excessive Daytime Sleepiness

France
Teva Pharmaceuticals USA

Completed

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Fasting

Healthy

United States
Teva Pharmaceuticals USA

Completed

Glyburide/Metformin 5 mg/500 mg Film-Coated Tablets, Fasting

Healthy

Canada
Pfizer

Completed

A Study To Observe Safety And Blood Concentrations Of PF-04995274 During And Following the Administration of Multiple Doses Of PF-04995274 In Healthy Adult And Healthy Elderly Volunteers.

Healthy

United States
Kobe University
Boehringer Ingelheim

Active, not recruiting

A Extension Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance ( EMPIRE-02 ) (EMPIRE-02)

Insulin Resistance - Type A | Insulin Resistance - Type B | Lipoatrophic Diabetes Mellitus | Insulin Resistance Syndrome

Japan
Impax Laboratories, LLC

Completed

IPX056 in Subjects With Established Spasticity Resulting From Multiple Sclerosis

Multiple Sclerosis

United States, Canada, Estonia, Latvia, Ukraine
Eisai Inc.

Completed

BLOOM-DM: Behavioral Modification and Lorcaserin for Overweight and Obesity Management in Diabetes Mellitus

Obesity

United States
Ain Shams University

Completed

Effect of Glucuronosyltransferase (UGT) Genetic Variation on Pharmacokinetics of Empagliflozin

Pharmacokinetics | Pharmacogenomic

Egypt
Kobe University
Boehringer Ingelheim

Active, not recruiting

A Study of Empagliflozin in Patients With Refractory Diabetes Mellitus With Insulin Resistance (EMPIRE-01)

Insulin Resistance - Type A | Insulin Resistance - Type B | Lipoatrophic Diabetes Mellitus | Insulin Resistance Syndrome

Japan
Neutec Ar-Ge San ve Tic A.Ş

Completed

The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity

Gastroesophageal Reflux Disease (GERD)

Turkey
Merck Sharp & Dohme LLC

Completed

MK3207 for Treatment of Acute Migraines (3207-005)

Migraine
Teva Pharmaceuticals USA

Completed

5 mg Glipizide/500 mg Metformin Hydrochloride Tablets, Non-Fasting

Healthy

United States
Manal Abdelmalek

Completed

JKB-121 for the Treatment of Nonalcoholic Steatohepatitis

Nonalcoholic Steatohepatitis

United States
University of California, San Diego
Juvenile Diabetes Research Foundation

Completed

Dapagliflozin Effects on Hypoglycemia

Type1 Diabetes Mellitus

United States
GlaxoSmithKline

Completed

Phase 2, Pharmacokinetics Study of Eltrombopag in Japanese Thrombocytopenic Subjects With Chronic Liver Disease

Liver Diseases

Japan
Steno Diabetes Center Copenhagen
Novo Nordisk A/S

Unknown

Renal Effects of Treatment With Empagliflozin Alone or in Combination With Semaglutide in Patients With Type 2 Diabetes and Albuminuria (EmpaSema)

Type 2 Diabetes With Renal Manifestations

Denmark
Mutual Pharmaceutical Company, Inc.

Completed

Fed Bioequivalence Study of Zolpidem Tartrate Tablets and Ambien® Tablets

Healthy | Therapeutic Equivalency
Sadat City University
Beni-Suef University

Completed

Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Diabete Type 2

Egypt
AmtixBio Co., Ltd.
Novotech (Australia) Pty Limited

Completed

A Study of ATB1651 in Adults With Mild to Moderate Onychomycosis

Onychomycosis

New Zealand

3

Subscribe